Heron Therapeutics (HRTX) News Today

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 32,820,000 shares, a growth of 7.7% from the June 15th total of 30,470,000 shares. Based on an average daily volume of 2,350,000 shares, the short-interest ratio is currently 14.0 days.

Heron Therapeutics (NASDAQ:HRTX) Stock Price Up 9.9%

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Stock analysts at Capital One Financial lifted their FY2028 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued to investors on Tuesday, July 2nd. Capital One Financial analyst T. Chiang now expects t

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 10,913 put options on the stock. This represents an increase of approximately 1,680% compared to the average volume of 613 put options.

Heron Therapeutics (NASDAQ:HRTX) Trading Up 8.9%

Heron Therapeutics (NASDAQ:HRTX) Shares Up 5%

Heron Therapeutics (NASDAQ:HRTX) Shares Down 3.9%

Rodman & Renshaw assumed coverage on Heron Therapeutics in a research note on Thursday. They set a "buy" rating and a $7.00 price target on the stock.

Heron Therapeutics (NASDAQ:HRTX) Hits New 52-Week High at $3.91

Heron Therapeutics (NASDAQ:HRTX) Stock Price Down 5.4%

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 30,270,000 shares, a growth of 10.9% from the April 30th total of 27,290,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 12.6 days.

Heron Therapeutics (NASDAQ:HRTX) Sets New 12-Month High at $3.65

Franklin Resources Inc. lowered its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,404,795 shares of the biotechnology company's stock after selling 5

Heron Therapeutics (NASDAQ:HRTX) Reaches New 12-Month High at $3.36

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities researchers at Capital One Financial upped their FY2026 earnings estimates for shares of Heron Therapeutics in a research note issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now expects that the biotechnology

Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday.

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 27,290,000 shares, a growth of 7.3% from the April 15th total of 25,430,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is presently 11.6 days.

Monaco Asset Management SAM grew its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 219.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,226,475 shares of the biotechnology co

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk lifted their Q2 2024 earnings estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now anticipat

Needham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday.

Heron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588518)

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotec

Capital One Financial started coverage on Heron Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $6.00 price objective for the company.